Skip to main content

Advertisement

SpringerLink
Log in

HSP90: a promising broad-spectrum antiviral drug target

  • Review
  • Published:
Archives of Virology Aims and scope Submit manuscript

Abstract

The emergence of antiviral drug-resistant mutants is the most important issue in current antiviral therapy. As obligate parasites, viruses require host factors for efficient replication. An ideal therapeutic target to prevent drug-resistance development is represented by host factors that are crucial for the viral life cycle. Recent studies have indicated that heat shock protein 90 (HSP90) is a crucial host factor that is required by many viruses for multiple phases of their life cycle including viral entry, nuclear import, transcription, and replication. In this review, we summarize the most recent advances regarding HSP90 function, mechanisms of action, and molecular pathways that are associated with viral infection, and provide a comprehensive understanding of the role of HSP90 in the immune response and exosome-mediated viral transmission. In addition, several HSP90 inhibitors have entered clinical trials for specific cancers that are associated with viral infection, which further implies a crucial role for HSP90 in the malignant transformation of virus-infected cells; as such, HSP90 inhibitors exhibit excellent therapeutic potential. Finally, we describe the challenge of developing HSP90 inhibitors as anti-viral drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Navarromarí JM, Mayoralcortés JM, Pérezruiz M, Rodríguezbaño J, Carratalá J, Gallardogarcía V (2010) Influenza a (H1N1) virus infection in humans: review to 30th October 2009. Enfermedades Infecciosas Y Microbiología Clínica 28(7):446–452

    Article  Google Scholar 

  2. Stadler K, Masignani V, Eickmann M, Becker S, Abrignani S, Klenk HD, Rappuoli R (2003) SARS—beginning to understand a new virus. Nat Rev Microbiol 1(3):209–218

    Article  CAS  PubMed  Google Scholar 

  3. Chun TW, Moir S, Fauci AS (2015) HIV reservoirs as obstacles and opportunities for an HIV cure. Nat Immunol 16(6):584–589

    Article  CAS  PubMed  Google Scholar 

  4. Krammer F, Palese P (2015) Advances in the development of influenza virus vaccines. Nat Rev Drug Discov 14(3):167–182

    Article  CAS  PubMed  Google Scholar 

  5. Clercq ED, Herdewijn P (2002) Strategies in the design of antiviral drugs. Nat Rev Drug Discov 1(1):13–25

    Article  PubMed  CAS  Google Scholar 

  6. Organization WH (2016) Global report on early warning indicators of HIV drug resistance: technical report

  7. Piret J, Boivin G (2010) Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 55(2):459–472

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC (2011) Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol 152(4):367–379

    Article  CAS  PubMed  Google Scholar 

  9. Fedson DS (2006) Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis Off Publ Infectious Dis Soc Am 43(2):199–205. doi:10.1086/505116

    Article  CAS  Google Scholar 

  10. Marjuki H, Alam MI, Ehrhardt C, Wagner R, Planz O, Klenk HD, Ludwig S, Pleschka S (2006) Membrane accumulation of influenza A virus hemagglutinin triggers nuclear export of the viral genome via protein kinase Calpha-mediated activation of ERK signaling. J Biol Chem 281(24):16707–16715. doi:10.1074/jbc.M510233200

    Article  CAS  PubMed  Google Scholar 

  11. Sgarbanti R, Nencioni L, Amatore D, Coluccio P, Fraternale A, Sale P, Mammola CL, Carpino G, Gaudio E, Magnani M, Ciriolo MR, Garaci E, Palamara AT (2011) Redox regulation of the influenza hemagglutinin maturation process: a new cell-mediated strategy for anti-influenza therapy. Antioxid Redox Signal 15(3):593–606. doi:10.1089/ars.2010.3512

    Article  CAS  PubMed  Google Scholar 

  12. Shim HY, Quan X, Yi YS, Jung G (2011) Heat shock protein 90 facilitates formation of the HBV capsid via interacting with the HBV core protein dimers. Virology 410(1):161–169

    Article  CAS  PubMed  Google Scholar 

  13. Ju HQ, Xiang YF, Xin BJ, Pei Y, Lu JX, Wang QL, Xia M, Qian CW, Ren Z, Wang SY (2011) Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11. Bioorg Med Chem Lett 21(6):1675–1677

    Article  CAS  PubMed  Google Scholar 

  14. Zur HH (1991) Viruses in human cancers. Science 254(5035):1167

    Article  Google Scholar 

  15. Deepti J, Munira Q, Neha G, Rajnish J, Nitin G (2009) Association of Epstein Barr virus infection (EBV) with breast cancer in rural indian women. Plos One 4(12):e8180

    Article  CAS  Google Scholar 

  16. Mazouni C, Fina F, Romain S, Ouafik L, Bonnier P, Brandone J-M, Martin P-M (2011) Epstein-Barr virus as a marker of biological aggressiveness in breast cancer. Br J Cancer 104(2):332

    Article  CAS  PubMed  Google Scholar 

  17. Zhoulei L, Nicolas G, Ken H, Alexandra J, Michaela A, Annette F, Anja B, Axel W, Christian P, Markus S, Andreas B, Ulrich K, Tobias D (2012) FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy. Cancer Res 72(19):5014–5024

  18. Oki Y, Younes A, Knickerbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin J (2015) Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica 100(7):e272

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Robson M, Goldfarb S, Drullinsky P, Sugarman S, Wasserheit-Leiblich C, Fasano J, Moynahan ME, D’Andrea G, Lim K, Reddington L, Haque S, Patil S, Bauman L, Vukovic V, El-Hariry I, Hudis C, Modi S (2014) A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin Breast Cancer 14(3):154–160. doi:10.1016/j.clbc.2013.12.012

    Article  CAS  PubMed  Google Scholar 

  20. Agyeman AS, Jun WJ, Proia DA, Kim CR, Skor MN, Kocherginsky M, Conzen SD (2016) Hsp90 inhibition results in glucocorticoid receptor degradation in association with increased sensitivity to paclitaxel in triple-negative breast cancer. Hormones Cancer 7(2):114–126. doi:10.1007/s12672-016-0251-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Geller R, Taguwa S (1823) Frydman J (2011) Broad action of Hsp90 as a host chaperone required for viral replication☆. Biochimica Et Biophysica Acta 3:698–706

    Google Scholar 

  22. Nakagawa SI, Umehara T, Matsuda C, Kuge S, Sudoh M, Kohara M (2007) Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochem Biophys Res Commun 353(4):882–888

    Article  CAS  PubMed  Google Scholar 

  23. Joshi P, Maidji E, Stoddart CA (2016) Inhibition of heat shock protein 90 prevents HIV rebound. J Biol Chem 291(19):10332–10346. doi:10.1074/jbc.M116.717538

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Chiosis G, Vilenchik M, Kim J, Solit D (2004) Hsp90: the vulnerable chaperone. Drug Discov Today 9(20):881–888. doi:10.1016/S1359-6446(04)03245-3

    Article  CAS  PubMed  Google Scholar 

  25. Taipale M, Krykbaeva I, Koeva M, Kayatekin C, Westover K, Karras G, Lindquist S (2012) quantitative analysis of Hsp90-client interactions reveals principles of substrate recognition. Cell 150(5):987–1001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Sellers RP, Alexander LD, Johnson VA, Lin CC, Savage J, Corral R, Moss J, Slugocki TS, Singh EK, Davis MR (2010) Design and synthesis of Hsp90 inhibitors: exploring the SAR of sansalvamide A derivatives. Bioorg Med Chem 18(18):6822–6856

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Hoyle C, Smyllie H, Leak D (2015) Measles virus infection inactivates cellular protein phosphatase 5 with consequent suppression of Sp1 and c-Myc activities. J Virol 89(19):9709–9718

    Article  CAS  Google Scholar 

  28. Filone CM, Caballero IS, Dower K, Mendillo ML, Cowley GS, Santagata S, Rozelle DK, Yen J, Rubins KH, Hacohen N (2014) The master regulator of the cellular stress response (HSF1) is critical for orthopoxvirus infection. PLoS Pathog 10(2):e1003904

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Anderson I, Low JS, Weston S, Weinberger M, Zhyvoloup A, Labokha AA, Corazza G, Kitson RA, Moody CJ, Marcello A (2014) Heat shock protein 90 controls HIV-1 reactivation from latency. Proc Natl Acad Sci 111(15):1528–1537

    Article  CAS  Google Scholar 

  30. Liu D, Wu AD, Cui L, Hao R, Wang Y, He J, Guo D (2014) Hepatitis B virus polymerase suppresses NF-κB signaling by inhibiting the activity of IKKs via interaction with Hsp90β. Plos One 9(3):e91658–e91658

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Song HL, Ran S, Mi NL, Kim CS, Lee H, Kong YY, Kim H, Jang SK (2008) A molecular chaperone glucose-regulated protein 94 blocks apoptosis induced by virus infection†. Hepatology 47(3):854–866

    Article  PubMed  CAS  Google Scholar 

  32. Rathore APS, Haystead T, Das PK, Merits A, Ng ML, Vasudevan SG (2014) Chikungunya virus nsP3 & nsP4 interacts with HSP-90 to promote virus replication: HSP-90 inhibitors reduce CHIKV infection and inflammation in vivo ☆. Antivir Res 103(1):7–16

    Article  CAS  PubMed  Google Scholar 

  33. Jeon YK, Park CH, Kim KY, Li YC, Kim J, Kim YA, Paik JH, Park BK, Kim CW, Kim YN (2007) The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation. J Pathol 213(2):170–179

    Article  CAS  PubMed  Google Scholar 

  34. Kotsiopriftis M, Tanner JE, Alfieri C (2005) Heat shock protein 90 expression in Epstein-Barr virus-infected B cells promotes gammadelta T-cell proliferation in vitro. J Virol 79(11):7255–7261

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Sun X, Kenney SC (2010) Hsp90 inhibitors: a potential treatment for latent EBV infection? Cell Cycle 9(9):1665–1666

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R (2013) Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood 122(16):2837–2847

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Field N, Low W, Daniels M, Howell S, Daviet L, Boshoff C, Collins M (2003) KSHV vFLIP binds to IKK-γ to activate IKK. J Cell Sci 116(Pt18):3721–3728

    Article  CAS  PubMed  Google Scholar 

  38. Wei B, Cui Y, Huang Y, Liu H, Li L, Li M, Ruan KC, Zhou Q, Wang C (2015) Tom70 mediates Sendai virus-induced apoptosis on mitochondria. J Virol 89(7):3804–3818

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Yang K, Shi H, Qi R, Sun S, Tang Y, Zhang B, Wang C (2006) Hsp90 regulates activation of interferon regulatory factor 3 and TBK-1 stabilization in Sendai virus-infected cells. Mol Biol Cell 17(3):1461–1471

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Basta S, Stoessel R, Basler M, van den Broek M, Groettrup M (2005) Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. J Immunol 175(2):796–805. doi:10.4049/jimmunol.175.2.796

    Article  CAS  PubMed  Google Scholar 

  41. Bukong TN, Momen-Heravi F, Kodys K, Bala S, Szabo G (2014) Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90. PLoS Pathog 10(10):e1004424. doi:10.1371/journal.ppat.1004424

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Kouwaki T, Fukushima Y, Daito T, Sanada T, Yamamoto N, Mifsud EJ, Leong CR, Tsukiyama-Kohara K, Kohara M, Matsumoto M, Seya T, Oshiumi H (2016) Extracellular vesicles including exosomes regulate innate immune responses to hepatitis B virus infection. Front Immunol. doi:10.3389/fimmu.2016.00335

    Google Scholar 

  43. Thery C, Zitvogel L, Amigorena S (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2(8):569–579. doi:10.1038/nri855

    CAS  PubMed  Google Scholar 

  44. Anderson MR, Kashanchi F, Jacobson S (2016) Exosomes in viral disease. Neurotherapeutics 13(3):535–546

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Bukong TN, Hou W, Kodys K, Szabo G (2013) Ethanol facilitates hepatitis C virus replication via up-regulation of GW182 and heat shock protein 90 in human hepatoma cells. Hepatology 57(1):70–80

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Keryerbibens C, Piochedurieu C, Villemant C, Souquère S, Nishi N, Hirashima M, Middeldorp J, Busson P (2006) Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer 6(1):1–8

    Article  Google Scholar 

  47. Sutmuller RPM, Brok MHMGMd, Kramer M, Bennink EJ, Toonen LWJ, Kullberg BJ, Joosten LA, Akira S, Netea MG, Adema GJ, Sutmuller RP et al (2006) Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Investig. 116(2):485–494

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Duerfeldt AS, Peterson LB, Maynard JC, Ng CL, Eletto D, Ostrovsky O, Shinogle HE, Moore DS, Argon Y, Nicchitta CV (2012) Development of a Grp94 inhibitor. J Am Chem Soc 134(23):9796–9804

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Hiscott J (2007) Convergence of the NF-kappaB and IRF pathways in the regulation of the innate antiviral response. Cytokine Growth Factor Rev 18(5–6):483–490

    Article  CAS  PubMed  Google Scholar 

  50. Severa M, Fitzgerald KA (2007) TLR-mediated activation of type i ifn during antiviral immune responses: fighting the battle to win the war. Curr Top Microbiol Immunol 316(1):167–192

    CAS  PubMed  Google Scholar 

  51. Pomerantz JL, Baltimore D (2002) Two pathways to NF-kappaB. Mol Cell 10(4):693–695

    Article  CAS  PubMed  Google Scholar 

  52. Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K, Cruciat C, Eberhard D, Gagneur J, Ghidelli S (2004) A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol 6(2):97–105

    Article  CAS  PubMed  Google Scholar 

  53. Field NLW, Daniels M, Howell S, Daviet L, Boshoff C, Collins M (2003) KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci 116(18):3721–3728

    Article  CAS  PubMed  Google Scholar 

  54. Citri A, Harari D, Shohat G, Ramakrishnan P, Gan J, Lavi S, Eisenstein M, Kimchi A, Wallach D, Pietrokovski S (2006) Hsp90 recognizes a common surface on client kinases. J Biol Chem 281(20):14361–14369

    Article  CAS  PubMed  Google Scholar 

  55. Lewis J, Devin A, Miller A, Lin Y, Rodriguez Y, Neckers L, Liu ZG (2000) Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation. J Biol Chem 275(14):10519–10526

    Article  CAS  PubMed  Google Scholar 

  56. Lee MN, Roy M, Ong SE, Mertins P, Villani AC, Li W, Dotiwala F, Sen J, Doench JG, Orzalli MH (2013) Identification of regulators of the innate immune response to cytosolic DNA and retroviral infection by an integrative approach. Nat Immunol 14(2):179

    Article  CAS  PubMed  Google Scholar 

  57. Chen G, Cao P, Goeddel DV (2002) TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol Cell 9(2):401–410

    Article  CAS  PubMed  Google Scholar 

  58. Eames HL, Udalova IA (2014) Interferon regulatory factors: role in transcriptional regulation of macrophage plasticity and activation. Springer, New York

    Google Scholar 

  59. Wendel HG, De SE, Fridman JS, Malina A, Ray S, Kogan S, Cordoncardo C, Pelletier J, Lowe SW (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428(6980):332–337

    Article  CAS  PubMed  Google Scholar 

  60. Jane EP, Premkumar DR, Morales A, Foster KA, Pollack IF (2014) Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells. J Pharmacol Exp Ther 350(1):22

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Tu Y, Gardner A, Lichtenstein A (2000) The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res 60(23):6763–6770

    CAS  PubMed  Google Scholar 

  62. Fillmore GC, Wang Q, Carey MJ, Kim CH, Elenitoba-Johnson KS, Lim MS (2005) Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas. Leuk Lymphoma 46(12):1765

    Article  CAS  PubMed  Google Scholar 

  63. Slupianek A, Nieborowskaskorska M, Hoser G, Morrione A, Majewski M, Xue L, Morris SW, Wasik MA, Skorski T (2001) Role of phosphatidylinositol 3-kinase-akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 61(5):2194–2199

    CAS  PubMed  Google Scholar 

  64. Dutton A, Reynolds GM, Dawson CW, Young LS, Murray PG (2005) Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin’s lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol 205(4):498

    Article  CAS  PubMed  Google Scholar 

  65. Morrison JA, Gulley ML, Pathmanathan R, Raabtraub N (2004) Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res 64(15):5251–5260

    Article  CAS  PubMed  Google Scholar 

  66. Jaffe ES (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, France

  67. Sun X, Barlow EA, Ma S, Hagemeier SR, Duellman SJ, Burgess RR, Tellam J, Khanna R, Kenney SC (2010) Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism. Proc Natl Acad Sci USA 107(7):3146–3151

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Gao L, Harhaj EW (2013) HSP90 Protects the human T-cell leukemia virus type 1 (HTLV-1) tax oncoprotein from proteasomal degradation to support NF-κB activation and HTLV-1 replication. J Virol 87(24):13640–13654

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Tsou YL, Lin YW, Chang HW, Lin HY, Shao HY, Yu SL, Liu CC, Chitra E, Sia C, Chow YH (2013) Heat shock protein 90: role in enterovirus 71 entry and assembly and potential target for therapy. Plos One 8(10):e77133–e77133

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Burch AD, Weller SK (2005) Herpes simplex virus type 1 DNA polymerase requires the mammalian chaperone hsp90 for proper localization to the nucleus. J Virol 79(16):10740–10749

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Zhong M, Zheng K, Chen M, Xiang Y, Jin F, Ma K, Qiu X, Wang Q, Peng T, Kitazato K, Wang Y (2014) Heat-shock protein 90 promotes nuclear transport of herpes simplex virus 1 capsid protein by interacting with acetylated tubulin. PLoS One 9(6):e99425. doi:10.1371/journal.pone.0099425

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  72. Chase G, Tao D, Fodor E, Bo WL, Mayer D, Schwemmle M, Brownlee G (2008) Hsp90 inhibitors reduce influenza virus replication in cell culture. Virology 377(2):431–439

    Article  CAS  PubMed  Google Scholar 

  73. Momose F, Naito T, Yano K, Sugimoto S, Morikawa Y, Nagata K (2002) Identification of Hsp90 as a stimulatory host factor involved in influenza virus RNA synthesis. J Biol Chem 277(47):45306–45314

    Article  CAS  PubMed  Google Scholar 

  74. Naito T, Momose F, Kawaguchi A, Nagata K (2007) Involvement of Hsp90 in assembly and nuclear import of influenza virus RNA polymerase subunits. J Virol 81(3):1339–1349

    Article  CAS  PubMed  Google Scholar 

  75. Panella S, Marcocci ME, Celestino I, Valente S, Zwergel C, Li PD, Nencioni L, Mai A, Palamara AT, Simonetti G (2016) MC1568 inhibits HDAC6/8 activity and influenza A virus replication in lung epithelial cells: role of Hsp90 acetylation. Future Med Chem 8(17):2017–2031

  76. Kawashima D, Kanda T, Murata T, Saito S, Sugimoto A, Narita Y, Tsurumi T (2013) Nuclear transport of Epstein-Barr virus DNA polymerase is dependent on the BMRF1 polymerase processivity factor and molecular chaperone Hsp90. J Virol 87(11):6482–6491

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Vendeville A, Rayne F, Bonhoure A, Bettache N, Montcourrier P, Beaumelle B (2004) HIV-1 Tat enters T cells using coated pits before translocating from acidified endosomes and eliciting biological responses. Mol Biol Cell 15(5):2347–2360

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Vozzolo L, Loh B, Gane PJ, Tribak M, Zhou L, Anderson I, Nyakatura E, Jenner RG, Selwood D, Fassati A (2010) Gyrase B inhibitor impairs HIV-1 replication by targeting Hsp90 and the capsid protein. J Biol Chem 285(50):39314–39328

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Sun X, Bristol JA, Iwahori S, Hagemeier SR, Meng Q, Barlow EA, Fingeroth JD, Tarakanova VL, Kalejta RF, Kenney SC (2013) Hsp90 Inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells. J Virol 87(18):10126–10138

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Czar MJ, Galigniana MD, Silverstein AM, Pratt WB (1997) Geldanamycin, a heat shock protein 90-binding benzoquinone ansamycin, inhibits steroid-dependent translocation of the glucocorticoid receptor from the cytoplasm to the nucleus†. Biochemistry 36(25):7776–7785

    Article  CAS  PubMed  Google Scholar 

  81. Das I, Basantray I, Mamidi P, Nayak TK, Mamidi P, Chattopadhyay S, Chattopadhyay S (2014) Heat shock protein 90 positively regulates Chikungunya virus replication by stabilizing viral non-structural protein nsP2 during infection. PLoS One 9(6):e100531. doi:10.1371/journal.pone.0100531

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Okamoto T, Nishimura Y, Ichimura T, Suzuki K, Miyamura T, Suzuki T, Moriishi K, Matsuura Y (2006) Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. Embo J 25(20):5015–5025

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Taguwa S, Okamoto T, Abe T, Mori Y, Suzuki T, Moriishi K, Matsuura Y (2008) Human butyrate-Induced transcript 1 interacts with hepatitis C virus NS5A and regulates viral replication. J Virol 82(6):2631–2641

    Article  CAS  PubMed  Google Scholar 

  84. Okamoto T, Omori H, Kaname Y, Abe T, Nishimura Y, Suzuki T, Miyamura T, Yoshimori T, Moriishi K, Matsuura Y (2008) A single-amino-acid mutation in hepatitis C virus NS5A disrupting FKBP8 interaction impairs viral replication. J Virol 82(7):3480–3489

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Waxman L, Whitney M, Pollok BA, Kuo LC, Darke PL (2001) Host cell factor requirement for hepatitis C virus enzyme maturation. Proc Natl Acad Sci USA 98(24):13931–13935

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Hu J, Flores D, Toft D, Wang X, Nguyen D (2004) Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function. J Virol 78(23):13122–13131

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Hu J, Seeger C (1996) Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc Natl Acad Sci USA 93(3):1060–1064

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Hu J, Anselmo D (2000) In vitro reconstitution of a functional duck hepatitis B virus reverse transcriptase: posttranslational activation by Hsp90. J Virol 74(24):11447–11455

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Wang X, Grammatikakis N, Hu J (2002) Role of p50/CDC37 in hepadnavirus assembly and replication. J Biol Chem 277(27):24361–24367

    Article  CAS  PubMed  Google Scholar 

  90. Vashist S, Urena L, Gonzalez-Hernandez MB, Choi J, De RA, Rocha-Pereira J, Neyts J, Hwang S, Wobus CE, Goodfellow I (2015) Molecular chaperone hsp90 is a therapeutic target for noroviruses. J Virol 89(12):6352–6363

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Connor JH, Mckenzie MO, Parks GD, Lyles DS (2007) Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses. Virology 362(1):109–119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Geller R, Andino R, Frydman J (2013) Hsp90 inhibitors exhibit resistance-free antiviral activity against respiratory syncytial virus. PLoS One 8(2):e56762. doi:10.1371/journal.pone.0056762

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Geller R, Vignuzzi M, Andino R, Frydman J (2007) Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractor. Genes Dev 21(2):195–205

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Chen W, Sin SH, Wen KW, Damania B, Dittmer DP (2012) Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins. PLoS Pathog 8(11):276–287

    Google Scholar 

  95. Miyata Y, Yahara I (2000) p53-independent association between SV40 large T antigen and the major cytosolic heat shock protein, HSP90. Oncogene 19(11):1477–1484

    Article  CAS  PubMed  Google Scholar 

  96. Ehrenkranz NJ, Meyer KF (2014) Multi-faceted proteomic characterization of host protein complement of rift valley fever virus virions and identification of specific heat shock proteins, including HSP90, as important viral host factors. Plos One 9(5):e93483

    Article  CAS  Google Scholar 

  97. Hung CY, Tsai MC, Wu YP, Wang RY (2011) Identification of heat-shock protein 90 beta in Japanese encephalitis virus-induced secretion proteins. J Gen Virol 92(Pt 12):2803–2809

    Article  CAS  PubMed  Google Scholar 

  98. Smith DR, Mccarthy S, Chrovian A, Olinger G, Stossel A, Geisbert TW, Hensley LE, Connor JH (2010) Inhibition of heat-shock protein 90 reduces Ebola virus replication. Antivir Res 87(2):187–194

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Czar MJ, Galigniana MD, Silverstein AM, Pratt WB (1997) Geldanamycin, a heat shock protein 90-binding benzoquinone ansamycin, inhibits steroid-dependent translocation of the glucocorticoid receptor from the cytoplasm to the nucleus. Biochemistry 36(25):7776–7785

    Article  CAS  PubMed  Google Scholar 

  100. Chou CK, Wang LH, Lin HM, Chi CW (1992) Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology 16(1):13–18

    Article  CAS  PubMed  Google Scholar 

  101. Chalepakis G, Arnemann J, Slater E, Brüller HJ, Gross B, Beato M (1988) Differential gene activation by glucocorticoids and progestins through the hormone regulatory element of mouse mammary tumor virus. Cell 53(3):371–382

    Article  CAS  PubMed  Google Scholar 

  102. Chou CK, Wang LH, Lin HM, Chi CW (1992) Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology 16(1):13–18

    Article  CAS  PubMed  Google Scholar 

  103. Li YH, Tao PZ, Liu YZ, Jiang JD (2004) Geldanamycin, a ligand of heat shock protein 90, inhibits the replication of herpes simplex virus type 1 in vitro. Antimicrob Agents Chemother 48(3):867–872

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Brice A, Moseley GW (2013) Viral interactions with microtubules: orchestrators of host cell biology? Future Virol 8(3):229–243

    Article  CAS  Google Scholar 

  105. Radtke K, Döhner K, Sodeik B (2006) Viral interactions with the cytoskeleton: a hitchhiker’s guide to the cell. Cell Microbiol 8(3):387–400

    Article  CAS  PubMed  Google Scholar 

  106. Kannan H (2009) The hepatitis E virus open reading frame 3 product interacts with microtubules and interferes with their dynamics. J Virol 83(13):6375–6382

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Perdiz D, Mackeh R, Poüs C, Baillet A (2010) The ins and outs of tubulin acetylation: more than just a post-translational modification? Cell Signal 23(5):763–771

    Article  PubMed  CAS  Google Scholar 

  108. Husain M, Gupta C (1997) Interactions of viral matrix protein and nucleoprotein with the host cell cytoskeletal actin in influenza viral infection. Curr Sci 73(1):40–47

    CAS  Google Scholar 

  109. Xuan C, Qiao W, Gao J, Liu M, Zhang X, Cao Y, Chen Q, Geng Y, Zhou J (2007) Regulation of microtubule assembly and stability by the transactivator of transcription protein of Jembrana disease virus. J Biol Chem 282(39):28800–28806

    Article  CAS  PubMed  Google Scholar 

  110. Basha W, Kitagawa R, Uhara M, Imazu H, Uechi K, Tanaka J (2005) Geldanamycin, a potent and specific inhibitor of Hsp90, inhibits gene expression and replication of human cytomegalovirus. Antivir Chem Chemother 16(2):135–146

    Article  CAS  PubMed  Google Scholar 

  111. Staff PO (2015) Heat shock protein 90 positively regulates chikungunya virus replication by stabilizing viral non-structural protein nsP2 during infection. Plos One 10(6):e100531

    Google Scholar 

  112. Hu J, Toft DO, Seeger C (1997) Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids. Embo J 16(1):59–68

    Article  PubMed  PubMed Central  Google Scholar 

  113. Taldone T, Sun W, Chiosis G (2009) Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem 17(6):2225–2235

    Article  CAS  PubMed  Google Scholar 

  114. Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, Heller G, Tong W, Cordoncardo C, Agus DB (2002) 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res Off J Am Assoc Cancer Res 8(5):986–993

    CAS  Google Scholar 

  115. Liao ZY, Zhen YS (2001) Advances in antitumor activity of the hsp90 inhibitor geldanamycin. Yao xue xue bao (Acta pharmaceutica Sinica) 36(9):716–720

    CAS  Google Scholar 

  116. Jez JM, Chen JC, Rastelli G, Stroud RM, Santi DV (2003) Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90. Chem Biol 10(4):361–368

    Article  CAS  PubMed  Google Scholar 

  117. Shen G, Wang M, Welch TR, Blagg BSJ (2006) Design, synthesis, and structureactivity relationships for chimeric inhibitors of Hsp90. J Org Chem 71(20):7618–7631

    Article  CAS  PubMed  Google Scholar 

  118. Roe SM, Obrien R, Ladbury JE, Piper PW, Pearl LH, Prodromou C (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42(2):260–266

    Article  CAS  PubMed  Google Scholar 

  119. Schumacher JA, Crockett DK, Elenitoba-Johnson KS, Lim MS (2007) Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells. Proteomics 7(15):2603–2616

    Article  CAS  PubMed  Google Scholar 

  120. Agnew EB, Wilson RH, Grem JL, Neckers L, Bi D, Takimoto CH (2001) Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 755(1–2):237–243

    Article  CAS  PubMed  Google Scholar 

  121. Gao J, Xiao S, Liu X, Wang L, Zhang X, Ji Q, Yue W, Mo D, Chen Y (2014) Inhibition of HSP90 attenuates porcine reproductive and respiratory syndrome virus production in vitro. Virol J 11(1):1–9

    Article  CAS  Google Scholar 

  122. Ujino S, Yamaguchi S, Shimotohno K, Takaku H (2009) Heat-shock protein 90 is essential for stabilization of the hepatitis C virus nonstructural protein NS3. J Biol Chem 284(11):6841–6846

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Kim MG, Moon JS, Kim EJ, Lee SH, Oh JW (2012) Destabilization of PDK1 by Hsp90 inactivation suppresses hepatitis C virus replication through inhibition of PRK2-mediated viral RNA polymerase phosphorylation. Biochem Biophys Res Commun 421(1):112

    Article  CAS  PubMed  Google Scholar 

  124. Chung CS, Chen CH, Ho MY, Huang CY, Liao CL, Chang W (2006) Vaccinia virus proteome: identification of proteins in vaccinia virus intracellular mature virion particles. J Virol 80(5):2127–2140

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Rice JW, Veal JM, Fadden RP, Barabasz AF, Partridge JM, Barta TE, Dubois LG, Huang KH, Mabbett SR, Silinski MA, Steed PM, Hall SE (2008) Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum 58(12):3765–3775. doi:10.1002/art.24047

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported by a research grant from the Natural Science Foundation of China 81573471, and Key Projects of Biological Industry Science and Technology of Guangzhou China (Grant number 201504291048224), and Science and Technology Plan Program of Guangdong Province China (Grant number 2015A050502028).

Author information

Author notes

  1. Yiliang Wang and Fujun Jin contributed equally to this work.

Authors and Affiliations

  1. Guangzhou Jinan Biomedicine Research and Development Center, Institute of Biomedicine, College of Life Science and Technology, Jinan University, Guangzhou, 510632, Guangdong, People’s Republic of China

    Yiliang Wang, Fujun Jin, Rongze Wang, Feng Li, Yanting Wu, Kaio Kitazato & Yifei Wang

  2. College of Pharmacy, Jinan University, Guangzhou, 510632, People’s Republic of China

    Yiliang Wang, Rongze Wang & Feng Li

  3. Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki, 852-8521, Japan

    Kaio Kitazato

Authors
  1. Yiliang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fujun Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rongze Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Feng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yanting Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kaio Kitazato
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yifei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Kaio Kitazato or Yifei Wang.

Ethics declarations

Conflict of interest

All authors declare that they have no conflicts of interest.

Ethical statements

The work has not been published previously and is not under consideration for publication elsewhere. All authors have agreed to the submission and to the order of their names on the title page; this article does not contain any studies with animals or humans performed by any of the authors. All tables and figures are original from our work; the original sources were cited in the text.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Y., Jin, F., Wang, R. et al. HSP90: a promising broad-spectrum antiviral drug target. Arch Virol 162, 3269–3282 (2017). https://doi.org/10.1007/s00705-017-3511-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00705-017-3511-1

Search

Navigation